Skip to main content
. 2020 Sep 28;9(17):e015307. doi: 10.1161/JAHA.119.015307

Figure 6. MFAP4 deficiency does not improve isoproterenol‐induced cardiac hypertrophy.

Figure 6

A, Polymerase chain reaction analysis of MFAP4 mRNA expression in the myocardium in each group (n=6). B and C, Statistical results for the ejection fraction and fractional shortening in the indicated group (n=10 for the WT‐Control and knockout mice (KO)‐Control groups; n=13 for the WT‐isoproterenol group; n=12 for the KO‐isoproterenol group). D and E, HW/BW and HW/tibia length ratios of WT and MFAP4‐KO mice after vehicle (control) or isoproterenol IP injection (n=12 for the WT‐Control and KO‐Con groups; n=23 for the WT‐isoproterenol group; n=13 for the KO‐isoproterenol group). F through I, The effects of isoproterenol on the mRNA expression of ANP, BNP, α‐MHC, and β‐MHC were determined by reverse transcription‐polymerase chain reaction analysis (n=6). J through L, Hematoxylin and eosin staining and wheat germ agglutinin‐fluorescein isothiocyanate isomer staining of the control or isoproterenol mice. J, 10× (scale bar: 400 μm), (K) 400× (scale bar: 50 μm). M, Quantification of the cross‐sectional areas in each group (n=6). N through P, Representative blots and quantitative results for ANP and β‐MHC protein expression in the myocardium in each group (n=6). ANP indicates atrial natriuretic peptide; HW/BW, heart weight/body weight; HW/TL, heart weight/tibia length; KO, knockout mice; NS, no statistically difference; WGA, wheat germ agglutinin; WT, wild‐type; and β‐MHC, β‐myosin heavy polypeptide. *P<0.05 compared with the corresponding control group.